The best predictors of which US counties’ patients are most likely to be prescribed higher-priced drugs are income, healthcare costs, and access to exercise opportunities, according to a new study published online in Nature Communications.
The best predictors of which US counties’ patients are most likely to be prescribed higher-priced drugs are income, healthcare costs, and access to exercise opportunities, according to a new study published online in Nature Communications.
Other factors such as state-level laws, insurance networks, or cultural preferences likely explain the remaining variance in brand preference across US counties, according to researchers Rachel D. Melamed, PhD, and Andrey Rzhetsky, PhD, of the University of Chicago. They concluded that a “patchwork” of contrasting medication cultures is in place across the nation, showing “geographically separated sub-Americas” that demonstrate the influences of racial composition, state-level healthcare laws, and wealth.
Their findings are based on an analysis of Truven MarketScan medical claims data covering more than 150 million individuals (nearly half the country’s population), followed for up to 10 years (2003-2013). The authors focused on comparing prescription rates of the 598 most highly prescribed drugs in more than 2300 US counties. The data contain a total of approximately 36 million patient-years.
Among the study’s findings are the following:
The study was funded by the DARPA Big Mechanism program and by National Institutes of Health grants.
Reference
Melamed RD, Rzhetsky A. Patchwork of contrasting medication cultures across the USA. Nature Communications.2018;9:4022. doi: 10.1038/s41467-018-06205-1.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Banking of Biosimilars: Insights From a Leading Health Economist
February 4th 2025Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect adoption, explored James D. Chambers, PhD, MPharm, MSc, associate professor at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, in an interview.
BioRationality: No More Biosimilars—Just Biogenerics
February 3rd 2025Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, recognizing them as "biogenerics" since physicochemical and in vitro biological comparisons are sufficient to ensure safety and efficacy.